TY - JOUR
T1 - Heart failure in women
T2 - An equal opportunity player in the expanding epidemic of heart failure
AU - Stevens, Gerin R.
AU - Kalman, Jill
N1 - Funding Information:
Despite the 1993 mandate by the National Institutes of Health, women are poorly represented in large clinical HF trials [55]. With its adequate inclusion of women, A-HeFT can stand as a model for other HF trials as we work to ensure the necessary representation of diverse populations in all clinical trials. Further research on women with HF will help define these needs and responses.
PY - 2008
Y1 - 2008
N2 - Heart failure has been described as an epidemic with increasing incidence and prevalence with the aging of the general population. Sex plays an important role in heart failure management given that women with heart failure typically are older, have nonischemic etiologies more often, and have better ventricular function than men with heart failure. This translates into better outcomes for women regardless of the cause of heart failure. Important differences exist in disease in women and men admitted with heart failure, and diagnostic and treatment strategies significantly differ. Despite a National Institutes of Health mandate in 1993, women are still underrepresented in clinical trials, making it difficult to extrapolate treatment data in a meaningful way.
AB - Heart failure has been described as an epidemic with increasing incidence and prevalence with the aging of the general population. Sex plays an important role in heart failure management given that women with heart failure typically are older, have nonischemic etiologies more often, and have better ventricular function than men with heart failure. This translates into better outcomes for women regardless of the cause of heart failure. Important differences exist in disease in women and men admitted with heart failure, and diagnostic and treatment strategies significantly differ. Despite a National Institutes of Health mandate in 1993, women are still underrepresented in clinical trials, making it difficult to extrapolate treatment data in a meaningful way.
UR - http://www.scopus.com/inward/record.url?scp=84873487784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873487784&partnerID=8YFLogxK
U2 - 10.1007/s12170-008-0040-1
DO - 10.1007/s12170-008-0040-1
M3 - Article
AN - SCOPUS:84873487784
VL - 2
SP - 210
EP - 216
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
SN - 1932-9520
IS - 3
ER -